Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 6/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | GHSR | Q92847 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249379 | 0.99 | CACNA1G (0.45) | HRH1KCNH2OPRK1ADORA3CNR1 | |
| SCHEMBL4248952 | 0.97 | DRD3 (0.44) | HRH1KCNH2OPRK1ADORA3CNR1 | |
| SCHEMBL4249535 | 0.91 | CACNA1G (0.45) | LMNADRD3CACNA1GDRD2CYP2C19 | |
| SCHEMBL4245578 | 0.86 | CACNA1G (0.49) | HRH1KCNH2OPRK1ADORA3CNR1 | |
| SCHEMBL4245546 | 0.86 | KCNH2 (0.44) | HRH1KCNH2OPRK1ADORA3CNR1 | |
| SCHEMBL4255404 | 0.85 | CACNA1G (0.47) | LMNADRD3HTR1ACACNA1GDRD2 | |
| SCHEMBL4253374 | 0.84 | MALT1 (0.48) | HRH1KCNH2OPRK1DRD3CHRM2 | |
| SCHEMBL13994813 | 0.83 | MALT1 (0.47) | HRH1KCNH2OPRK1ADORA3CNR1 | |
| SCHEMBL4245635 | 0.80 | CACNA1G (0.42) | HRH1DRD3ADRA1AHTR1ACACNA1G | |
| SCHEMBL4250460 | 0.80 | MALT1 (0.47) | HRH1KCNH2OPRK1DRD3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | claimed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | claimed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | claimed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | claimed |
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | disclosed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | HRH1 1585/4885KCNH2 31/4885OPRK1 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.